Combination antiretroviral therapy and indoleamine 2,3-dioxygenase in HIV infections: challenges and new opportunities

AIDS. 2016 Jul 17;30(11):1839-41. doi: 10.1097/QAD.0000000000001168.

Authors

Ali Ahmad¹, Vikram Mehraj, Mohammad-Ali Jenabian, Suzanne Samarani, Cecile Tremblay, Jean-Pierre Routy

Affiliation

¹ aLaboratory of Innate Immunity, Centre Hospitalier Universitaire (CHU) Staine-Justine Research Center bDepartment of Microbiology, Infectiology and Immunology cCentre Hospitalier Universite de Montreal (CHUM) dUniversity of Montreal eMcGill University Health Center, McGill University fDepartment of Biological Sciences, University of Quebec at Montreal (UQAM), Montreal, Quebec, Canada.

PMID: 27351927
DOI: 10.1097/QAD.0000000000001168

No abstract available

Publication types

Editorial
Comment

MeSH terms

HIV Infections*
Humans
Indoleamine-Pyrrole 2,3,-Dioxygenase*
Interferon-gamma

Substances

Indoleamine-Pyrrole 2,3,-Dioxygenase
Interferon-gamma